[
    [
        {
            "time": "2021-09",
            "original_text": "康泰生物：公司自主研发的13价肺炎球菌多糖结合疫苗为全球首创的双载体13价肺炎球菌多糖结合疫苗，于2021年9月获得药品注册证书",
            "features": {
                "keywords": [
                    "13价肺炎球菌多糖结合疫苗",
                    "全球首创",
                    "药品注册证书"
                ],
                "sentiment_score": 0.9,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药",
                    "疫苗"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "康泰生物：公司自主研发的13价肺炎球菌多糖结合疫苗为全球首创的双载体13价肺炎球菌多糖结合疫苗，于2021年9月获得药品注册证书",
                "Correlation": 10,
                "Sentiment": 9,
                "Importance": 9,
                "Impact": 8,
                "Duration": 8,
                "Entity_Density": 10,
                "Market_Scope": 6,
                "Time_Proximity": 5,
                "Headline_Structure": 7,
                "Source_Recency": 5
            }
        },
        {
            "time": "2021-10",
            "original_text": "康泰生物：2021年10月首次获得批签发证明，标志着13价肺炎球菌多糖结合疫苗可在国内外上市销售",
            "features": {
                "keywords": [
                    "13价肺炎球菌多糖结合疫苗",
                    "批签发证明",
                    "上市销售"
                ],
                "sentiment_score": 0.85,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药",
                    "疫苗"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "康泰生物：2021年10月首次获得批签发证明，标志着13价肺炎球菌多糖结合疫苗可在国内外上市销售",
                "Correlation": 10,
                "Sentiment": 9,
                "Importance": 9,
                "Impact": 9,
                "Duration": 9,
                "Entity_Density": 10,
                "Market_Scope": 7,
                "Time_Proximity": 4,
                "Headline_Structure": 8,
                "Source_Recency": 4
            }
        },
        {
            "time": "2021-06",
            "original_text": "康泰生物：新冠灭活疫苗III期临床试验6月下旬在海外进行第一针接种，目前在实施中",
            "features": {
                "keywords": [
                    "新冠灭活疫苗",
                    "III期临床试验",
                    "海外接种"
                ],
                "sentiment_score": 0.75,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药",
                    "疫苗"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "康泰生物：新冠灭活疫苗III期临床试验6月下旬在海外进行第一针接种，目前在实施中",
                "Correlation": 9,
                "Sentiment": 7,
                "Importance": 8,
                "Impact": 7,
                "Duration": 7,
                "Entity_Density": 10,
                "Market_Scope": 8,
                "Time_Proximity": 6,
                "Headline_Structure": 7,
                "Source_Recency": 6
            }
        },
        {
            "time": "2021-present",
            "original_text": "康泰生物：公司的腺病毒载体新冠疫苗近期已获得印度尼西亚国家药品和食品监管局紧急使用授权",
            "features": {
                "keywords": [
                    "腺病毒载体新冠疫苗",
                    "紧急使用授权",
                    "印度尼西亚"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药",
                    "疫苗"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "康泰生物：公司的腺病毒载体新冠疫苗近期已获得印度尼西亚国家药品和食品监管局紧急使用授权",
                "Correlation": 10,
                "Sentiment": 9,
                "Importance": 9,
                "Impact": 8,
                "Duration": 7,
                "Entity_Density": 10,
                "Market_Scope": 7,
                "Time_Proximity": 7,
                "Headline_Structure": 8,
                "Source_Recency": 7
            }
        },
        {
            "time": "2021-present",
            "original_text": "康泰生物：冻干水痘减毒活疫苗已完成Ⅲ期临床研究现场工作",
            "features": {
                "keywords": [
                    "冻干水痘减毒活疫苗",
                    "Ⅲ期临床研究",
                    "完成"
                ],
                "sentiment_score": 0.7,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药",
                    "疫苗"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "康泰生物：冻干水痘减毒活疫苗已完成Ⅲ期临床研究现场工作",
                "Correlation": 9,
                "Sentiment": 8,
                "Importance": 7,
                "Impact": 6,
                "Duration": 6,
                "Entity_Density": 10,
                "Market_Scope": 6,
                "Time_Proximity": 5,
                "Headline_Structure": 7,
                "Source_Recency": 5
            }
        },
        {
            "time": "2021-present",
            "original_text": "康泰生物：变异株的疫苗研发目前处于临床前研究阶段",
            "features": {
                "keywords": [
                    "变异株疫苗",
                    "临床前研究",
                    "研发"
                ],
                "sentiment_score": 0.6,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药",
                    "疫苗"
                ],
                "causal_factor": "true",
                "causal_impact": "neutral",
                "affected_by_time_series": "false",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "康泰生物：变异株的疫苗研发目前处于临床前研究阶段",
                "Correlation": 8,
                "Sentiment": 6,
                "Importance": 6,
                "Impact": 5,
                "Duration": 5,
                "Entity_Density": 10,
                "Market_Scope": 7,
                "Time_Proximity": 6,
                "Headline_Structure": 6,
                "Source_Recency": 6
            }
        },
        {
            "time": "2021-present",
            "original_text": "康泰生物：公司在开展3-17岁人群的临床现场",
            "features": {
                "keywords": [
                    "3-17岁人群",
                    "临床现场",
                    "开展"
                ],
                "sentiment_score": 0.65,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药",
                    "疫苗"
                ],
                "causal_factor": "true",
                "causal_impact": "neutral",
                "affected_by_time_series": "false",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "康泰生物：公司在开展3-17岁人群的临床现场",
                "Correlation": 8,
                "Sentiment": 7,
                "Importance": 6,
                "Impact": 5,
                "Duration": 5,
                "Entity_Density": 10,
                "Market_Scope": 6,
                "Time_Proximity": 6,
                "Headline_Structure": 6,
                "Source_Recency": 6
            }
        },
        {
            "time": "2021-present",
            "original_text": "康泰生物：冻干人用狂犬病疫苗（人二倍体细胞）生产注册申请已获得国家药品监督管理受理",
            "features": {
                "keywords": [
                    "冻干人用狂犬病疫苗",
                    "生产注册申请",
                    "受理"
                ],
                "sentiment_score": 0.7,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药",
                    "疫苗"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "康泰生物：冻干人用狂犬病疫苗（人二倍体细胞）生产注册申请已获得国家药品监督管理受理",
                "Correlation": 9,
                "Sentiment": 8,
                "Importance": 8,
                "Impact": 7,
                "Duration": 7,
                "Entity_Density": 10,
                "Market_Scope": 6,
                "Time_Proximity": 5,
                "Headline_Structure": 7,
                "Source_Recency": 5
            }
        }
    ]
]